Table 2.
Association of clinical features and ICD.
| ICDs Patients | Non-ICDs Patients | p | |
|---|---|---|---|
| Male | 70.27% | 64.29% | 0.5127 |
| Age (years) | 63.57 ± 8.97 | 63.12 ± 9.80 | 0.8319 |
| Age of onset (years) | 51.89 ± 9.59 | 53.24 ± 11.39 | 0.5256 |
| Disease duration (years) | 11.86 ± 4.87 | 9.97 ± 6.35 | 0.0341 |
| MDS-UPDRS part III in “OFF state” | 38.28 ± 16.29 | 40.84 ± 17.78 | 0.4931 |
| MDS-UPDRS part III in “ON state” | 18.37 ±12.29 | 18.97 ± 11.64 | 0.6499 |
| Motor fluctuation | 83.78% | 58.16% | 0.0053 |
| Sleep disorders | 67.56% | 47.96% | 0.0417 |
| Dopamine agonist use | 83.78% | 54.08% | 0.0015 |
| DA-LEDD | 170.78 ± 120.15 | 135.25 ± 236.60 | 0.0217 |
| MAO-B inhibitors | 27.03% | 18.37% | 0.2683 |
| Amantadine | 35.14% | 30.61% | 0.6149 |
| Levodopa | 94.59% | 87.76% | 0.2449 |
| LD-LEDD | 804.68 ± 536.98 | 954.73 ± 629.73 | 0.3038 |
| LD-LEDD (patients receiving only monotherapy) | 1625 ± 944.6 | 916.90 ± 527.20 | 0.0489 |
| Total LEDD | 1268.24 ± 645.56 | 1030.31 ± 624.33 | 0.0524 |
Data are shown as numbers and percentages for qualitative variables and mean ± SD for quantitative variables. DA—dopamine agonist; LEDD—levodopa equivalent daily dose; LD—levodopa; MDS-UPDRS—MDS Unified Parkinson’s Disease Rating Scale.